Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933782 | 0.81 | HRH3 (0.37) | HCAR3HRH3KDM4EALDH1A1 | |
| SCHEMBL2068723 | 0.79 | AOC3 (0.33) | HCAR3 | |
| SCHEMBL2033967 | 0.79 | DGAT1 (0.37) | — | |
| SCHEMBL4778674 | 0.77 | PKM (0.50) | — | |
| SCHEMBL4774964 | 0.76 | CKS1B (0.32) | — | |
| SCHEMBL8199502 | 0.76 | PKM (0.37) | POLBHRH3KDM4E | |
| SCHEMBL182698 | 0.74 | — | — | |
| SCHEMBL17316687 | 0.74 | — | — | |
| SCHEMBL4774563 | 0.73 | POLB (0.54) | POLBHSD17B10HRH3KDM4E | |
| SCHEMBL4770152 | 0.72 | SMN1; SMN2 (0.43) | MAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-8962835-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | claimed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
| EP-3552607-A2 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-9567348-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2710/4885HCAR3 3640/4885TRPV1 1971/4885 |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, ZAP70 | POLB 2979/4885HCAR3 3817/4885TRPV1 1743/4885 |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 3592/4885HCAR3 3910/4885TRPV1 1529/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | POLB 3100/4885HCAR3 3422/4885TRPV1 2045/4885 |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2710/4885HCAR3 3640/4885TRPV1 1971/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2710/4885HCAR3 3640/4885TRPV1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.